---
title: "China Resources Pharmaceutical's subsidiary BOYA BIOLOGY earned 343 million RMB in the first nine months, a decline of 16.8%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262923627.md"
description: "China Resources Pharmaceutical announced that its subsidiary BOYA BIOLOGY had a total operating revenue of 1.474 billion RMB for the nine months ending in September, an increase of 18.4% year-on-year. It recorded a net profit of 343 million RMB, a decline of 16.8%"
datetime: "2025-10-27T14:16:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262923627.md)
  - [en](https://longbridge.com/en/news/262923627.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262923627.md)
---

# China Resources Pharmaceutical's subsidiary BOYA BIOLOGY earned 343 million RMB in the first nine months, a decline of 16.8%

China Resources Pharmaceutical (03320.HK) announced that its subsidiary BOYA BIOLOGY (300294.SZ) achieved a total operating revenue of 1.474 billion RMB for the nine months ending in September, an increase of 18.4% year-on-year. It recorded a net profit of 343 million RMB, a decline of 16.8%

### Related Stocks

- [300294.CN](https://longbridge.com/en/quote/300294.CN.md)

## Related News & Research

- [PGW: FY26 saw double-digit revenue and EBITDA growth, strong cash flow, and a positive FY27 outlook](https://longbridge.com/en/news/295448351.md)
- [Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study](https://longbridge.com/en/news/295661585.md)
- [09:40 ETAQUAPASS Completes Enrollment in REFORM-HF Pivotal Trial, Results to Be Presented at Major Heart Failure Conference This Fall](https://longbridge.com/en/news/295416035.md)
- [Keymed Biosciences says Phase II trial of CM512 meets endpoints in chronic rhinosinusitis with nasal polyps](https://longbridge.com/en/news/295337751.md)
- [IT Tech Packaging tunda rilis laporan keuangan kuartal II 2026, ajukan pemberitahuan keterlambatan 10-Q](https://longbridge.com/en/news/295575415.md)